Skip to main content
SpringerLink
Log in

Immunotherapy for Other Malignancies

  • Chapter
  • First Online:
The Basics of Cancer Immunotherapy

  • 2347 Accesses

Abstract

Immune checkpoint inhibitors have demonstrated durable responses with tolerable toxicities in various advanced malignancies, and have gained FDA approval for treatments in diseases such as melanoma, lung cancer, renal cancer, and lymphoma. Recent research has focused on expanding the role of immunotherapy in multiple other solid tumor types that otherwise have very limited treatment options and a poor prognosis. The applications of immune checkpoint inhibitors in tumor types that are not yet covered in this book will be discussed, and the data from preclinical and clinical research will be reviewed here. However, given the limited space and the progressively evolving landscape of immunotherapy, this chapter is designed as an overview of the treatment options rather than a complete review of all the available trials and results. We would like to refer our readers to https://clinicaltrials.gov for the most up to date clinical trial options and status. More importantly, open discussion between patients and oncologists is highly recommended in order to formulate the most appropriate and effective treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 29.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 37.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ali, H. R., Provenzano, E., Dawson, S. J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J. A., Bowden, S. J., Twelves, C., Bartlett, J. M., Mahmoud, S. M., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D., & Caldas, C. (2014). Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Annals of Oncology, 25, 1536–1543.

    Article  Google Scholar 

  • Ali, H. R., Glont, S. E., Blows, F. M., Provenzano, E., Dawson, S. J., Liu, B., Hiller, L., Dunn, J., Poole, C. J., Bowden, S., Earl, H. M., Pharoah, P. D., & Caldas, C. (2015). PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 26, 1488–1493.

    Article  Google Scholar 

  • An, J. Y., Kim, H., Cheong, J. H., Hyung, W. J., Kim, H., & Noh, S. H. (2012). Microsatellite instability in sporadic gastric cancer: Its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. International Journal of Cancer, 131, 505–511.

    Article  Google Scholar 

  • Bang, Y. J., Doi, T., De Braud, F., Piha-Paul, S., Hollebecque, A., Razak, A. R. A., Lin, C. C., Ott, P. A., He, A. R., Yuan, S. S., Koshiji, M., Lam, B., & Aggarwal, R. (2015). Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028. European Journal of Cancer, 51, S112–S112.

    Article  Google Scholar 

  • Bendell, J. C., Kim, T. W., Goh, B. C., Wallin, J., Oh, D. Y., Han, S. W., Lee, C. B., Hellmann, M. D., Desai, J., Lewin, J. H., Solomon, B. J., Chow, L. Q. M., Miller, W. H., Gainor, J. F., Flaherty, K., Infante, J. R., Das-Thakur, M., Foster, P., Cha, E., & Bang, Y. J. (2016). Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). Journal of Clinical Oncology, 34(36), 4307–4453.

    Article  Google Scholar 

  • Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T. M., Alaparthy, S., Grosso, J. F., Korman, A. J., Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D. M., Gupta, A., & Wigginton, J. M. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine, 366, 2455–2465.

    Article  Google Scholar 

  • Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Aren Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., PAZ-ARES, L., RECK, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. The New England Journal of Medicine, 373, 123–135.

    Article  Google Scholar 

  • Cancer.Org. (2017). Cancer estimates.

    Google Scholar 

  • Cancer.Org. American Cancer Society.

    Google Scholar 

  • Crocenzi, T. S., El-Khoueiry, A. B., & Cheung, T. (2017). Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. Journal of Clinical Oncology, 35, 3541–3543.

    Google Scholar 

  • Denkert, C., Loibl, S., Noske, A., Roller, M., Muller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., Von Torne, C., Weichert, W., Engels, K., Solbach, C., Schrader, I., Dietel, M., & Von Minckwitz, G. (2010). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology, 28, 105–113.

    Article  Google Scholar 

  • Derks, S., Liao, X., Chiaravalli, A. M., Xu, X., Camargo, M. C., Solcia, E., Sessa, F., Fleitas, T., Freeman, G. J., Rodig, S. J., Rabkin, C. S., & Bass, A. J. (2016). Abundant PD-L1 expression in epstein-barr virus-infected gastric cancers. Oncotarget, 7, 32925–32932.

    Article  Google Scholar 

  • Dirix, L. Y., Takacs, I., Nikolinakos, P., Jerusalem, G., Arkenau, H. T., Hamilton, E. P., Von Heydebreck, A., Grote, H. J., Chin, K., & Lippman, M. E. (2016). Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor trial. Cancer Research, 76(4 Supplement), Abstract S1–04.

    Article  Google Scholar 

  • Disis, M. L., Patel, M. R., Pant, S., Hamilton, E. P., Lockhart, A. C., Kelly, K., Beck, J. T., Gordon, M. S., Weiss, G. J., Taylor, M. H., Chaves, J., Mita, A. C., Chin, K. M., Von Heydebreck, A., Cuillerot, J. M., & Gulley, J. L. (2016). Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. Journal of Clinical Oncology, 34(15_suppl), 5533.

    Google Scholar 

  • Doi, T., Piha-Paul, S. A., Jalal, S. I., Mai-Dang, H., Yuan, S., Koshiji, M., Csiki, I., & Bennouna, J. (2015). Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028. Journal of Clinical Oncology, 33(15_suppl), 4010.

    Google Scholar 

  • El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T. Y., Choo, S. P., Trojan, J., Welling, T. H. R., Meyer, T., Kang, Y. K., Yeo, W., Chopra, A., Anderson, J., Dela Cruz, C., Lang, L., Neely, J., Tang, H., Dastani, H. B., & Melero, I. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, 389, 2492–2502.

    Article  Google Scholar 

  • Emens, L. A., Braiteh, F., Cassier, P. A., Delord, J. P., Eder, J. P., & Fasso, M. (2015). Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Research, 75(15 Supplement), abstract 2859.

    Article  Google Scholar 

  • Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359–E386.

    Article  Google Scholar 

  • Ferris, R. L., Blumenschein, G., Jr., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., & Gillison, M. L. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 375, 1856–1867.

    Article  Google Scholar 

  • Frenel, J. S., Le Tourneau, C., O’neil, B. H., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C. A., Van Brummelen, E., Rugo, H. S., Thomas, S., Saraf, S., Chen, M., & Varga, A. (2016). Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. Journal of Clinical Oncology, 34(15_suppl), 5515.

    Google Scholar 

  • Fuchs, C. S., Doi, T., Jang, R. W.-J., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., Garrido, M., Golan, T., mandala, m., Wainberg, Z. A., Catenacci, D. V. T., Bang, Y.-J., Wang, J., Koshiji, M., Dalal, R. P., & Yoon, H. H. (2017). KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. ASCO, 35(31), 3519–3634.

    Google Scholar 

  • Fury, M.,Butler, M., Ou, S., Balmanoukian, A., et al. (2014). Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in head and neck cancer. ESMO Meeting 2014, Poster No 988PD.

    Google Scholar 

  • Gani, F., Nagarajan, N., Kim, Y., Zhu, Q., Luan, L., Bhaijjee, F., Anders, R. A., & Pawlik, T. M. (2016). Program death 1 immune checkpoint and tumor microenvironment: Implications for patients with intrahepatic cholangiocarcinoma. Annals of Surgical Oncology, 23, 2610–2617.

    Article  Google Scholar 

  • Gao, Q., Wang, X. Y., Qiu, S. J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B. Z., Shi, Y. H., Xiao, Y. S., Xu, Y., & Fan, J. (2009). Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clinical Cancer Research, 15, 971–979.

    Article  Google Scholar 

  • Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., Matsumura, N., Abiko, K., Baba, T., Yamaguchi, K., Ueda, A., Hosoe, Y., Morita, S., Yokode, M., Shimizu, A., Honjo, T., & Konishi, I. (2015). Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology, 33, 4015–4022.

    Article  Google Scholar 

  • Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S., Stover, E., Strickland, K. C., D'andrea, A. D., Wu, C. J., Matulonis, U. A., & Konstantinopoulos, P. A. (2015). Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers with Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncology, 1, 1319–1323.

    Article  Google Scholar 

  • Kang, Y.-K., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., & Yoshikawa, T. (2017). Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized,phase III trial. Journal of Clinical Oncology, 35, 2–2.

    Article  Google Scholar 

  • Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'angelo, S. P., Shih, K. C., Lebbe, C., Linette, G. P., Milella, M., Brownell, I., Lewis, K. D., Lorch, J. H., Chin, K., Mahnke, L., Von Heydebreck, A., Cuillerot, J. M., & Nghiem, P. (2016). Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. The Lancet Oncology, 17, 1374–1385.

    Article  Google Scholar 

  • Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Satoh, T., Iwasa, S., Muro, K., Yasui, H., Minashi, K., Yamaguchi, K., Ohtsu, A., Doki, Y., & Kitagawa, Y. (2017). Nivolumab treatment for oesophageal squamous-cell carcinoma: An open-label, multicentre, phase 2 trial. The Lancet Oncology, 18, 631–639.

    Article  Google Scholar 

  • Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., Kiezun, A., Hammerman, P. S., Mckenna, A., Drier, Y., Zou, L., Ramos, A. H., Pugh, T. J., Stransky, N., Helman, E., Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortes, M. L., Auclair, D., Saksena, G., Voet, D., Noble, M., Dicara, D., Lin, P., Lichtenstein, L., Heiman, D. I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. M., Lohr, J., Landau, D. A., Wu, C. J., Melendez-Zajgla, J., Hidalgo-Miranda, A., Koren, A., Mccarroll, S. A., Mora, J., Crompton, B., Onofrio, R., Parkin, M., Winckler, W., Ardlie, K., Gabriel, S. B., Roberts, C. W. M., Biegel, J. A., Stegmaier, K., Bass, A. J., Garraway, L. A., Meyerson, M., Golub, T. R., Gordenin, D. A., Sunyaev, S., Lander, E. S., & Getz, G. (2013). Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499, 214–218.

    Article  Google Scholar 

  • Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., Biedrzycki, B., Donehower, R. C., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Duffy, S. M., Goldberg, R. M., De La Chapelle, A., Koshiji, M., Bhaijee, F., Huebner, T., Hruban, R. H., Wood, L. D., Cuka, N., Pardoll, D. M., Papadopoulos, N., Kinzler, K. W., Zhou, S., Cornish, T. C., Taube, J. M., Anders, R. A., Eshleman, J. R., Vogelstein, B., & Diaz, L. A., Jr. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine, 372, 2509–2520.

    Article  Google Scholar 

  • Le, D. T., Uram, J. N., Wang, H., Bartlett, B., Kemberling, H., Eyring, A., Azad, N. S., Laheru, D., Donehower, R. C., Crocenzi, T. S., Goldberg, R. M., Fisher, G. A., Lee, J. J., Greten, T. F., Koshiji, M., Kang, S. P., Anders, R. A., Eshleman, J. R., Vogelstein, B., & Diaz, L. A. (2016). Programmed death-1 blockade in mismatch repair deficient colorectal cancer. Journal of Clinical Oncology, 34(15_suppl), 103.

    Google Scholar 

  • Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., Wong, F., Azad, N. S., Rucki, A. A., Laheru, D., Donehower, R., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Greten, T. F., Duffy, A. G., Ciombor, K. K., Eyring, A. D., Lam, B. H., Joe, A., Kang, S. P., Holdhoff, M., Danilova, L., Cope, L., Meyer, C., Zhou, S., Goldberg, R. M., Armstrong, D. K., Bever, K. M., Fader, A. N., Taube, J., Housseau, F., Spetzler, D., Xiao, N., Pardoll, D. M., Papadopoulos, N., Kinzler, K. W., Eshleman, J. R., Vogelstein, B., Anders, R. A., & Diaz, L. A., Jr. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357, 409–413.

    Article  Google Scholar 

  • Lee, J. M., Cimino-Mathews, A., Peer, C. J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., CAO, L., Harrell, M. I., Swisher, E., Houston, N., Botesteanu, D. A., Taube, J. M., Thompson, E., Ogurtsova, A., Xu, H. Y., Nguyen, J., Ho, T. W., Figg, W. D., & Kohn, E. C. (2017). Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women's cancers: A dose-escalation, phase I study. Journal of Clinical Oncology, 35, 2193.

    Article  Google Scholar 

  • Liu, Y. X., Wang, X. S., Wang, Y. F., Hu, X. C., Yan, J. Q., Zhang, Y. L., Wang, W., Yang, R. J., Feng, Y. Y., GAO, S. G., & FENG, X. S. (2016). Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: A meta-analysis. Oncotargets and Therapy, 9, 2649–2654.

    Google Scholar 

  • Morris, V. K., Salem, M. E., Nimeiri, H., Iqbal, S., Singh, P., Ciombor, K., Polite, B., Deming, D., Chan, E., Wade, J. L., Xiao, L. C., Bekaii-Saab, T., Vence, L., Blando, J., Mahvash, A., Foo, W. C., Ohaji, C., Pasia, M., Bland, G., Ohinata, A., Rogers, J., Mehdizadeh, A., Banks, K., Lanman, R., Wolff, R. A., Streicher, H., Allison, J., Sharma, P., & Eng, C. (2017). Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study. The Lancet Oncology, 18, 446–453.

    Article  Google Scholar 

  • Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., Mcree, A. J., Lin, C. C., Pathiraja, K., Lunceford, J., Emancipator, K., Juco, J., Koshiji, M., & Bang, Y. J. (2016). Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. The Lancet Oncology, 17, 717–726.

    Article  Google Scholar 

  • Nanda, R., Chow, L. Q., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., Karantza, V., & Buisseret, L. (2016). Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. Journal of Clinical Oncology, 34, 2460–2467.

    Article  Google Scholar 

  • Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L., MARGOLIN, K., MITCHELL, A., Olencki, T., Pardoll, D. M., Reddy, S. A., Shantha, E. M., Sharfman, W. H., Sharon, E., Shemanski, L. R., Shinohara, M. M., Sunshine, J. C., Taube, J. M., Thompson, J. A., Townson, S. M., Yearley, J. H., Topalian, S. L., & Cheever, M. A. (2016). PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. The New England Journal of Medicine, 374, 2542–2552.

    Article  Google Scholar 

  • Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., Tsushima, F., Otsuki, N., Yagita, H., Azuma, M., & Nakajima, Y. (2005). Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clinical Cancer Research, 11, 2947–2953.

    Article  Google Scholar 

  • Ott, P. A., Bang, Y. J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J. M., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M., & Soria, J. C. (2017). Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. Journal of Clinical Oncology, 35, 2535–2541.

    Article  Google Scholar 

  • Overman, M. J., Lopez, C. D., Benson, A., Neelapu, S. S., Mettu, N. B., Ko, A. H., Chung, V. M., Nemunaitis, J. J., Reeves, J. A., Bendell, J. C., Philip, P. A., Dalal, R., Fardis, M., Greer, J., Wang, X. L., Inamdar, S., Lannutti, B. J., Rothbaum, W., Izumi, R., & Javle, M. M. (2016). A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). Journal of Clinical Oncology, 34(15_suppl), 4130.

    Google Scholar 

  • Overman, M. J., Mcdermott, R., Leach, J. L., Lonardi, S., Lenz, H. J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V., Cao, Z. A., Ledeine, J. M., Maglinte, G. A., Kopetz, S., & Andre, T. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. The Lancet Oncology, 18, 1182–1191.

    Article  Google Scholar 

  • Palefsky, J. M., Giuliano, A. R., Goldstone, S., Moreira, E. D., Aranda, C., Jessen, H., Hillman, R., Ferris, D., Coutlee, F., Stoler, M. H., Marshall, J. B., Radley, D., Vuocolo, S., Haupt, R. M., Guris, D., & Garner, E. I. O. (2011). HPV Vaccine against anal HPV infection and anal intraepithelial neoplasia. The New England Journal of Medicine, 365, 1576–1585.

    Article  Google Scholar 

  • Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., Miller, M. L., Rekhtman, N., Moreira, A. L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E. B., Merghoub, T., Wolchok, J. D., Schumacher, T. N., & Chan, T. A. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348, 124–128.

    Article  Google Scholar 

  • Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., & Rosenberg, S. A. (2010). Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. Journal of Immunotherapy, 33, 828–833.

    Article  Google Scholar 

  • Sabatier, R., Finetti, P., Mamessier, E., Adelaide, J., Chaffanet, M., Ali, H. R., Viens, P., Caldas, C., Birnbaum, D., & Bertucci, F. (2015). Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, 6, 5449–5464.

    Article  Google Scholar 

  • Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van Den Eynden, G., Baehner, F. L., Penault-Llorca, F., Perez, E. A., Thompson, E. A., Symmans, W. F., Richardson, A. L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., FLORIS, G., Sparano, J., Kos, Z., Nielsen, T., Rimm, D. L., Allison, K. H., Reis-Filho, J. S., Loibl, S., Sotiriou, C., Viale, G., Badve, S., Adams, S., Willard-Gallo, K., Loi, S., & INTERNATIONAL, T. W. G. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs working group 2014. Annals of Oncology, 26, 259–271.

    Article  Google Scholar 

  • Schellens, J. H. M., Marabelle, A., Zeigenfuss, S., Ding, J., Pruitt, S. K., & Chung, H. C. (2017). Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 studye. Journal of Clinical Oncology, 35(15_suppl), 5514.

    Google Scholar 

  • Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008). Epitope landscape in breast and colorectal cancer. Cancer Research, 68, 889–892.

    Article  Google Scholar 

  • Segal, N. H., Antonia, S. J., Brahmer, J. R., Maio, M., Blake-Haskins, A., Li, X., Vasselli, J., Ibrahim, R. A., Lutzky, J., & Khieif, S. (2014). Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Journal of Clinical Oncology, 32(15_suppl), 3002.

    Google Scholar 

  • Segal, N. H., Ou, S. H. I., Balmanoukian, A. S., Massarelli, E., Brahmer, J. R., Weiss, J., Schoffski, P., Antonia, S. J., Massard, C., Zandberg, D. P., Maher, C., Khleif, S., Jin, X., Rebelatto, M., Steele, K., Antal, J., Gupta, A., & Spreafico, A. (2016). Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. Annals of Oncology, 27.

    Google Scholar 

  • Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., Mcdermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., Mcmiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., Mcdonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., & Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine, 366, 2443–2454.

    Article  Google Scholar 

  • Varga, A., Piha-Paul, S. A., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Johnson, E. A., Cheng, J. D., Yuan, S., Rubin, E. H., & Matei, D. E. (2015). Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. Journal of Clinical Oncology, 33(15_suppl), 5510.

    Google Scholar 

  • Wang, B. J., Bao, J. J., Wang, J. Z., Wang, Y., Jiang, M., Xing, M. Y., Zhang, W. G., Qi, J. Y., Roggendorf, M., Lu, M. J., & Yang, D. L. (2011). Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World Journal of Gastroenterology, 17, 3322–3329.

    Article  Google Scholar 

  • Weber, J. S., D'angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., Linette, G. P., Thomas, L., Lorigan, P., Grossmann, K. F., Hassel, J. C., Maio, M., Sznol, M., Ascierto, P. A., Mohr, P., Chmielowski, B., Bryce, A., Svane, I. M., Grob, J. J., Krackhardt, A. M., Horak, C., Lambert, A., Yang, A. S., & Larkin, J. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16, 375–384.

    Article  Google Scholar 

  • Zhang, M. H., Dong, Y. D., Liu, H. T., Wang, Y., Zhao, S., Xuan, Q. J., Wang, Y., & Zhang, Q. Y. (2016). The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: A meta-analysis of 10 studies with 1,901 patients. Scientific Reports, 94(6), e515.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA

    Yiyi Yan

Authors
  1. Yiyi Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA

    Haidong Dong

  2. Department of Oncology, Department of Medicine/Division of Hematology, Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA

    Svetomir N. Markovic

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yan, Y. (2018). Immunotherapy for Other Malignancies. In: Dong, H., Markovic, S. (eds) The Basics of Cancer Immunotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-70622-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-70622-1_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-70621-4

  • Online ISBN: 978-3-319-70622-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation